Possible Protective Effect of Low Dose of Papaverine on ANIT Induce Cholestasis in Rat

Authors

  • Doaa Adnan Atshan Ministry of Health and Environment, Alnuman Teaching Hospital, Baghdad, Iraq.
  • Munaf H. Zalzala Department of Pharmacology and Toxicology, College of Pharmacy, University of Baghdad, Baghdad, Iraq.

DOI:

https://doi.org/10.31351/vol32issSuppl.pp118-126

Keywords:

intrahepatic cholestasis,ANIT,papaverine

Abstract

Abstract

Intrahepatic cholestasis is clinical syndrome which cause either by defect in synthesis or bile acid flow, the pathophysiology of cholestasis is complicated by a number of  variables, including oxidative stress, inflammatory response, and  dysregulation of bile acid transporter . Rats, mice, and guinea pigs were utilized as experimental animals, and ANIT was administered to them in order to create a model that closely resembled intrahepatic cholestasis in human. This study examined the protective effects of papaverine, a non-narcotic opium alkaloid derived from papaver somniferum and discovered as an FXR agonist, on cholestasis in rats induced by alpha-naphthylisothiocyanate (ANIT). Rats utilized in this study divided  into 3 groups (10 rats per each groups), group I (control) or vehicle group  rat administered corn oil (1ml/kg) once daily 48 hour before sacrifice group II rats orally administered alpha-naphthylisothiocyanate (ANIT) 100mg/kg single dose 48hour before sacrifice  group III rats administered 100mg/kg papaverine orally  for 7 consecutive days and  at day 5  rat administered alpha-naphthylisothiocyanate (ANIT) The results showed that papaverine treatment decreased alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), total bilirubin, total bile acid, as well as increased antioxidant enzyme GPX and decreased MDA and inflammatory mediators tumor necrosis factor TNF- and interleukin IL1-β. In conclusion, papaverine may have a protective effect to alleviate ANIT-induced cholestasis and may be a therapeutic target to treat cholestasis.

How to Cite

1.
Adnan Atshan D, Munaf H. Zalzala. Possible Protective Effect of Low Dose of Papaverine on ANIT Induce Cholestasis in Rat. Iraqi Journal of Pharmaceutical Sciences [Internet]. 2023 Nov. 3 [cited 2024 Nov. 21];32(Suppl.):118-26. Available from: https://bijps.uobaghdad.edu.iq/index.php/bijps/article/view/2561

Publication Dates

References

Zalzala MH, Kareem VS. The Safranal Effect against Cyclophosphamide-Induced Liver Injury. Iraqi Journal of Pharmaceutical Sciences. 2021 Dec 11;30(2):208-13.

Ahmad HA, Kathem SH. Thymoquinone Attenuates Immune Mediated Liver Injury Induced by Concanavalin A in Mice. Iraqi Journal of Pharmaceutical Sciences. 2021 Dec 9;30(2):50-7.

Bertolini A, Fiorotto R, Strazzabosco M. Bile acids and their receptors: Modulators and therapeutic targets in liver inflammation. InSeminars in immunopathology 2022 Jul (Vol. 44, No. 4, pp. 547-564). Berlin/Heidelberg: Springer Berlin Heidelberg.

Onofrio FQ, Hirschfield GM. The pathophysiology of cholestasis and its relevance to clinical practice. Clinical liver disease. 2020 Mar;15(3):110.

Chen L, Wei S, Liu H, Li J, Jing M, Tong Y, Li R, Wen J, Zhan H, Zhao Y. Paeoniflorin protects against ANIT-induced cholestatic liver injury in rats via the activation of SIRT1-FXR signaling pathway. Evidence-Based Complementary and Alternative Medicine. 2021 Sep 2;2021.

Sultana H, Komai M, Shirakawa H. The Role of Vitamin K in Cholestatic Liver Disease. Nutrients. 2021 Aug;13(8):2515.

Trauner M, Claudel T, Fickert P, Moustafa T, Wagner M. Bile acids as regulators of hepatic lipid and glucose metabolism. Digestive diseases. 2010;28(1):220-4.

van de Wiel SM, Bijsmans IT, van Mil SW, van de Graaf SF. Identification of FDA-approved drugs targeting the Farnesoid X Receptor. Scientific reports. 2019 Feb 18;9(1):1-1

Downloads

Published

2023-11-03